Report
Pneumococcal AMC outcomes and impact evaluation
This evaluation assesses the extent to which the Advanced Market Commitment (AMC) pilot has achieved its stated objectives and the overarching goal to “reduce morbidity and mortality from pneumococcal disease by accelerating the development, availability and uptake of pneumococcal conjugate vaccines (PCVs)”. The AMC pilot was started in 2005 and officially launched in 2007 with a collective US$ 1.5 billion commitment from the Bill and Melinda Gates Foundation, Canada, Italy, Norway, Russian Federation and United Kingdom.
Authors
Languages
- English
Publication year
2016
Type
Report
Categories
- Global initiatives
Diseases
- Pneumococcal disease
Organisations
- Gavi, the Vaccine Alliance
Tags
- Performance monitoring
- Planning, budgeting and financing
WHO Regions
- African Region
